Laboratory-Clinic Interface
Variability in bioavailability of small molecular tyrosine kinase inhibitors

https://doi.org/10.1016/j.ctrv.2015.03.005Get rights and content

Highlights

  • smTKIs generally exhibit a low and variable bioavailability.

  • Both pharmaceutical and physiological factors contribute to this.

  • Especially solubility and metabolism seem to be essential to the variability.

  • Knowledge and consideration of these factors may improve smTKI-therapy.

Abstract

Small molecular tyrosine kinase inhibitors (smTKIs) are in the centre of the very quickly expanding area of personalized chemotherapy and oral applicability thereof. The number of drugs in this class is rapidly growing, with twenty current approvals by both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). The drugs are, however, generally characterized by a poor oral, and thus variable, bioavailability. This results in significant variation in plasma levels and exposure. The cause is a complex interplay of factors, including poor aqueous solubility, issued permeability, membrane transport and enzymatic metabolism. Additionally, food and drug–drug interactions can play a significant role. The issues related with an impaired bioavailability generally receive little attention. To the best of our knowledge, this article is the first to provide an overview of the factors that determine the bioavailability of the smTKIs.

Introduction

The development of anticancer drugs is a very quickly expanding area in which two trends are clearly present. In the first place new agents are designed fulfilling the requirements for personalized medicine. The advancement of techniques such as (cell-based) high throughput screening and the diverse possibilities in molecular modeling have lead to a therapeutic target-based drug discovery regime [1], [2]. Along with the evolution of synthetical methods, compounds are found that are highly specific and demonstrate great affinity for molecular targets [3], [4], [5], [6]. Individual tumors, and their specific targets, can be genetically characterized and a suitable ‘personalized’ chemotherapy can be appointed depending on the neoplasm’s genotype [7]. The second movement is also referred to as ‘the intravenous to oral switch’. The last decade has shown an increasing number of anticancer drugs that are administered orally [8], [9]. Currently, most of the anticancer drugs that are in development or recently approved are destined for oral ingestion. Unlike previous conventions, oral therapy in cancer has proven efficient and less costly [10]. On top of that comes the preference of the patient, especially since oral ingestion can take place in the home setting and is highly convenient compared to intravenous administration [8].

In the middle of these trends stands a promising and growing group of drugs; the tyrosine kinase inhibitors (TKIs). In the past ten years, the size of this group has doubled [11], [12], [13]. The TKIs target specific parts of tyrosine kinase receptor proteins that play an important role in the intracellular signaling pathways in tumor cells. Their interference leads to a deregulation of essential cell functions such as proliferation and differentiation [14]. One of the two types of TKIs, the small molecular TKIs (smTKIs) with an intracellular activity, are without exception administered orally. Currently, twenty of these small molecular compounds are approved by both the EMA and the FDA. General information on the drugs is found in Table 1 [11], [12]. This review will focus on these particular compounds. The other type of TKI is a group of monoclonal antibodies, which possess a larger molecular structure and interfere with signal transduction by binding extracellularly and are administrated intravenously. The small molecular inhibitors have proven useful in the therapy of certain types and lines of cancer [6], [11], [12], [15]. Additionally, smTKIs may be prescribed as alternatives when other therapeutic options have failed or are not appropriate. Although the development of personalized oral chemotherapy is very promising, the nature of the selection process leads to drugs, however, that are hindered by a low and variable bioavailability (F). This aspect and its causes are underexposed subjects in literature. Indeed, smTKIs may be very potent and suitable for certain tumor types. When they are unable to reach their target in sufficient quantities, the therapy will be suboptimal or even failing. This review will address the bioavailability-determining factors for the smTKIs and presents prerequisites in both the marketed formulations and chemotherapeutical practice to minimize the reduction and variation in oral F. It is important to be aware of and understand the various factors that determine F and its variability of the smTKIs. This will allow for the betterment of their use in chemotherapy.

The fraction of the total ingested drug that reaches the systemic circulation unchanged, and is transported to its therapeutic target, is defined and termed (absolutely) bioavailable (F) [16]. Fig. 1 schematically presents the different processes that govern the extent of F. F is the product of the drug fraction that is absorbed (FF), the dose that reaches the hepatic portal vein unchanged (FG) and the fraction of the dose that is not metabolized by enzymes in the liver (FH), as presented in Eq. (1) [16], [17],F=FFFGFH

In each of the before mentioned steps, an amount of drug might be lost. Whatever the cause, a low F is associated with an increased intra- and interpatient variability in drug plasma concentration [18]. Registration texts and other studies, as far as could be accessed, show significant inter-individual variation in important pharmacokinetic parameters of all smTKIs [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37]. This may result in possibly dangerous situations for patients that experience extensively low, or high, exposure to the substances. Many anticancer drugs are known to exhibit a small therapeutic window, where the minimum therapeutic dose and the maximum tolerated dose (MTD) are close to each other [38]. The same is true for the smTKIs, with a possible exception of Dabrafenib, Imatinib, Gefitinib and Pazopanib [13], [19], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52]. As a consequence of pharmacokinetic variation, inter-individual differences in therapeutic dose and MTD should be taken into account. Under- and overdosing are thus potential hazards of oral chemotherapy. Thus, careful dose titration and adjustments are required to assure an adequate therapy, in both effect and tolerance. Hence, therapeutic drug monitoring (TDM) is upcoming for smTKIs [38].

The human oral F of the smTKIs is largely unknown or inaccessible in the public domain and published values are generally low and the exposure is variable [39], [53], [54]. The determination of oral F-values requires a comparison between oral and IV-administration. IV-solutions with smTKIs are often difficult to prepare due to the poor water solubility of the drugs (see Section ‘Dissolution’). Table 1 presents the currently known values. Low values for oral F may be due to one or more of several factors. It is often the consequence of a complex interplay of both physicochemical and physiological processes. Furthermore, it may also be influenced by concomitant administration of other drugs. Additionally, the intake of food or certain habits of life-style may exert an impact on F.

The Biopharmaceutics Classification System (BCS) can aid to clarify possible absorption-related causes of an impaired F. Solubility and permeability of a drug are recognized as fundamental parameters in the absorption process [55]. The BCS combines data on the in vitro solubility in the intestinal tract of the drug substance and data on the extent of total permeation through the gut wall and appoints a class to it [55], [56], [57]. Fig. 2 summarizes the assignment of the classes and presents the classes of the smTKIs [58], [59], [37]. Classifications may be interpreted as signals for formulation design (class II and IV) or physicochemical modifications (class III and IV) [58].

The newer Biopharmaceutics Drug Disposition Classification system (BDDCS) correlates the passive permeability rate of drug with their metabolic elimination [60], [61], [62]. Here, passive permeability is considered ‘good’ when elimination is largely governed by metabolism (>70%) [63]. Fig. 2 presents the BDDCS classification between braces where it differs from the BCS classification. The discrepancies between the BCS and BDDCS classes may be due to the fact that BCS is based on total permeation and BDDCS on the passive permeability rate [64]. The latter does not account for interaction with membrane transporters.

Section snippets

Dissolution

The first step in becoming bioavailable is the dissolution of the drug substance into the gastrointestinal fluids. Since only the solute form of the drug can be absorbed, the release from the oral formulation is an important parameter. In fact, the major cause for the different absorption profiles of drugs from various products is dissolution [16]. The dissolution rate of a drug substance can be described using the Noyes-Whitney equation (Eq. 2) [65], [66]:dWdt=DACs-Chin which dW/dt is the

Permeability and passive transport

The degree of permeability describes the extent of (intestinal) membrane penetration of a drug [86]. The passing of molecules occurs through passive or facilitated diffusion, (active) carrier mediated or paracellular transport [87], [88]. Lipophile, large and relatively uncharged drugs are moved transcellularly through cell membranes. This passive transport is a or the major route of movement across membranes of many drugs [86], [89]. The same is reported for the smTKIs, although this is not

Elderly

The process of aging involves changes in physiology and the functioning of organ systems. Important hepatic changes when considering drugs are a decrease in liver mass and CYP450 content. Kidneys decrease in mass with age and renal blood flow lessens. Gastric motility slows down and the secretion of gastric juices decreases [126]. Cancer is generally considered to be a disease of the elderly, with 60% of the diagnoses of cancer taking place in patients aged 75 and over [127]. Although

Food

The ingestion of food can cause the F of co-ingested drugs to change. The mechanisms by which this happens are not fully understood, but some clarification may be obtained from physiological changes caused by the presence of food [133], [134]. The pH-values in the gastric environment may rise from 1–3.5 to 3.0–6.0 due to buffering and dilutant effects of food stuffs [135]. The proximal part of the duodenum does experience lower pH values when gastric emptying takes place [136]. Overall,

Discussion

The advances in drug discovery have led to a particularly useful niche of chemotherapeutics, the orally applicable smTKIs as key representatives. Although the development of personalized oral chemotherapy is very promising, the nature of the selection process leads to drugs that are hindered by a low and variable F. This low and variable F does not appear to be a hindrance in the wielding of the drugs, but might prove to be troublesome in further expanding the use of these compounds. High or

Conclusion

The smTKI-group generally suffers from a low and variable F, a problem that is receiving little attention in literature. This review presents the various causes of the low and variable F of the smTKIs and provides possible means to enhance F and to reduce variability. Special attention is directed towards food and pH-dependent interactions, which have consequences for the therapeutic regimen of most of the smTKIs. Physicochemical, physiological and pharmacological data is far from complete.

Funding and conflicts of interest

No sources of funding were used to assist in the preparation of this manuscript. The authors declare no conflict of interest.

References (200)

  • H.A. Bradeen et al.

    Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

    Blood

    (2006)
  • L.Z. Benet

    The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development

    J Pharm Sci

    (2013)
  • C.A.S. Bergström et al.

    Is the full potential of the biopharmaceutics classification system reached?

    Eur J Pharm Sci

    (2014)
  • P. Macheras et al.

    Keeping a critical eye on the science and the regulation of oral drug absorption: a review

    J Pharm Sci

    (2013)
  • S.S. Jambhekar et al.

    Drug dissolution: significance of physicochemical properties and physiological conditions

    Drug Discov Today

    (2013)
  • E. Sjögren et al.

    In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim

    Eur J Pharm Sci

    (2013)
  • C. Reppas et al.

    Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs

    Gastroenterology

    (1991)
  • P. Augustijns et al.

    A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption

    Eur J Pharm Sci

    (2014)
  • A. Newman et al.

    Assessing the performance of amorphous solid dispersions

    J Pharm Sci

    (2012)
  • D. Ouellet et al.

    Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors

    J Pharm Sci

    (2013)
  • J.J. Sheng et al.

    Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed

    J Pharm Sci

    (2008)
  • M. Estudante et al.

    Intestinal drug transporters: an overview

    Adv Drug Deliv Rev

    (2013)
  • B. Stieger et al.

    Organic anion-transporting polypeptides

    Curr Top Membr

    (2014)
  • Y.-H. Liu et al.

    Multidrug resistance-associated proteins and implications in drug development

    Clin Exp Pharmacol Physiol

    (2010)
  • P. Kohonen et al.

    Cancer biology, toxicology and alternative methods development go hand-in-hand

    Basic Clin Pharmacol Toxicol

    (2014)
  • M. Pinne et al.

    Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery

    Expert Opin Drug Discov

    (2014)
  • N. Charette et al.

    Ras in digestive oncology: from molecular biology to clinical implications

    Curr Opin Oncol

    (2014)
  • P. Chieffi

    An overview on new anticancer molecular targets in human testicular germ cell tumors

    Rend Lincei

    (2014)
  • G. Minuti et al.

    Protein kinase inhibitors to treat non-small-cell lung cancer

    Expert Opin Pharmacother

    (2014)
  • J.W. Tyner

    Functional genomics for personalized cancer therapy

    Sci Transl Med

    (2014)
  • G. Liu et al.

    Patient preferences for oral versus intravenous palliative chemotherapy

    J Clin Oncol

    (1997)
  • European Medicines Agency (EMA). European Public Assessments Reports (EPARs). <http://www.ema.europa.eu>, [accessed...
  • US Food and Drug administration (FDA). Product Label Descriptions. <http://fda.gov>, [accessed...
  • Administration Australian therapeutic goods. Australian Public Assessment Reports for prescription medicines (AUSPARs)....
  • J.T. Hartmann et al.

    Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects

    Curr Drug Metab

    (2009)
  • M.R. Harrison

    Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?

    Clin Med Insights Oncol

    (2011)
  • M. Rowland et al.

    Clinical pharmacokinetics; concepts and applications

    (1994)
  • E.T. Hellriegel et al.

    Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies

    Clin Pharmacol Ther

    (1996)
  • US Food and Drug administration (FDA). Clinical pharmacology and biopharmaceutics reviews0. <http://fda.gov>, [accessed...
  • M. Freiwald et al.

    Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

    Cancer Chemother Pharmacol

    (2014)
  • M. Garrett et al.

    Population pharmacokinetic analysis of axitinib in healthy volunteers

    Br J Clin Pharmacol

    (2014)
  • P.-H. Hsyu et al.

    Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

    Cancer Chemother Pharmacol

    (2013)
  • P.-H. Hsyu et al.

    Abstract A195: a population pharmacokinetic (PPK) model of bosutinib (BOS)

    Mol Cancer Ther

    (2011)
  • D. Ouellet et al.

    Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites

    J Clin Pharmacol

    (2014)
  • M. Fukudo et al.

    Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer

    Clin Pharmacokinet

    (2013)
  • M. White-Koning et al.

    Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children

    Clin Cancer Res

    (2011)
  • A.M. Filppula et al.

    Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response

    Drug Metab Dispos

    (2013)
  • C. Yoo et al.

    Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure

    Invest New Drugs

    (2012)
  • C. Tanaka et al.

    Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants

    J Clin Pharmacol

    (2011)
  • H.I. Hurwitz et al.

    Phase I trial of pazopanib in patients with advanced cancer

    Clin Cancer Res

    (2009)
  • Cited by (108)

    View all citing articles on Scopus
    View full text